Abstract：Objective: To investigate the value of contrast-enhanced ultrasound (CEUS) combined with serum peroxide-reducing protein 6 (PRDX6) and potential transforming growth factor β binding protein 2 (LTBP2) in the prediction of sentinel lymph node metastasis (SLNM) in breast cancer (BC). Methods: A total of 116 BC patients diagnosed by pathology from January 2022 to June 2024 were selected as the study subjects, and all patients underwent CEUS examination before surgery. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum PRDX6 and LTBP2 levels, and sentinel lymph node biopsy (SLNB) and pathological examination were performed during surgery. According to the occurrence of SLNM, 116 patients with BC were divided into a metastatic group (n=46) and a non-metastatic group (n=70). The general data and serum PRDX6 and LTBP2 levels of BC patients in the metastatic group and the non-metastatic group were compared. The receiver operating characteristic (ROC) curve was used to analyze the predictive performance of CEUS, serum PRDX6 and LTBP2 alone and in combination with the detection of SLNM in BC patients. Results: There were no significant differences in age, BMI, menopause, and tumor location between the metastatic group and the non-metastatic group in BC patients (P>0.05), but there were significant differences in tumor diameter, T stage, vascular invasion, and ER status (P<0.05). The sensitivity and specificity of CEUS in the diagnosis of SLNM were 89.13% (41/46) and 88.57% (62/70), respectively, and the accuracy was 88.79% (103/116), respectively, and CEUS was highly consistent with the "gold standard" (Kappa=0.768, P<0.05). The serum levels of PRDX6 and LTBP2 in the metastatic group were significantly higher than those in the non-metastatic group (P<0.05). The results of ROC curves showed that the sensitivity and specificity of PRDX6 in the diagnosis of SLNM were 91.3% and 82.7%, respectively, and the sensitivity and specificity of LTBP2 in the diagnosis of SLNM were 71.7% and 63.1%, respectively. The sensitivity and specificity of CEUS combined with serum PRDX6 and LTBP2 in the diagnosis of SLNM were 91.3% and 82.7%, respectively, and the AUC of the combined diagnosis was significantly higher than that of CEUS, serum PRDX6 and LTBP2 alone (Z=2.548, 2.205, 1.990, P<0.05). Conclusion: CEUS combined with serum PRDX6 and LTBP2 has high predictive value for SLNM in patients with BC, which can provide an important reference for clinical diagnosis and treatment of BC.
李娟, 高婧钰, 程艳, 周莹, 晏如意. 超声造影联合血清PRDX6 LTBP2对乳腺癌前哨淋巴结转移的预测价值[J]. 河北医学, 2025, 31(7): 1215-1219.
LI Juan, et al. The Predictive Value of Contrast-Enhanced Ultrasound Combined with Serum PRDX6 and LTBP2 in the Sentinel Lymph Node Metastasis of Breast Cancer. HeBei Med, 2025, 31(7): 1215-1219.
[1] Chen ZH,Tian Y,Zhou GL,et al.CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling[J].Breast Cancer Res,2023,25(1):22-37. [2] 王云翔,刘俊锋,徐升.Qct-4、VEGF-D、L-selectin表达情况对乳腺癌患者发生前哨淋巴结转移的预测价值[J].中国现代医药杂志,2023,25(12):62-66. [3] 曹思薇,刘兴远,程晓英,等.基于FFDM、超声特征及临床因素的列线图模型预测乳腺癌前哨淋巴结转移的价值[J].现代肿瘤医学,2024,32(22):4304-4311. [4] 葛妍,张海见,张媛,等.常规超声、超声弹性成像和经皮超声造影在乳腺癌前哨淋巴结诊断中的价值比较[J].分子影像学杂志,2022,45(4):546-550. [5] 周菊英,郭强,张子宁,等.超声造影联合声触诊组织成像量化技术诊断乳腺癌前哨淋巴结的效能[J].临床与病理杂志,2022,42(11):2648-2653. [6] Li H,Wu Z,Zhong R,et al.PRDX6 knockout restrains the malignant progression of intrahepatic cholangiocarcinoma[J].Med Oncol,2022,39(12):250-258. [7] Li P,Sun D.Advanced diagnostic imaging of sentinel lymph node in early stage breast cancer[J].Clin Ultrasound,2022,50(3):415-421. [8] Machado P,Liu JB,Needleman L,et al.Sentinel lymph node identification in patients with breast cancer using lymphosonography[J].Ultrasound Med Biol,2023,49(2):616-625. [9] Lagal DJ,Lopez-Grueso MJ,Pedrajas JR,et al.Loss of PRDX6 aborts proliferative and migratory signaling in hepatocarcinoma cell lines[J].Antioxidants (Basel),2023,12(6):1153. [10] 马淑萍,蒙玉娜,党春艳,等.锰超氧化物歧化酶和过氧化物酶6在弥漫性大B细胞淋巴瘤中的表达及临床意义[J].陕西医学杂志,2021,50(9):1154-1157. [11] 林晶,金成日,玄云泽.β-Lapachone通过诱导ROS生成调控口腔鳞状细胞癌增殖与凋亡的机制研究[J].口腔医学研究,2022,38(1):39-44. [12] Li Y,Meng F,Sui C,et al.CircWHSC1 expedites cervical cancer progression via miR-532-3p/LTBP2 axis[J].Mol Cell Biochem,2022,477(6):1669-1679.
2025, Vol. 31 
冀公网安备13080202000786号